The APA Guideline stresses the importance ... may be indicated for catatonic schizophrenia, treatment-resistant schizophrenia, or severe depression that cannot be managed with medications.

The management of treatment resistant schizophrenia does remain controversial [48] but guidelines have some consistency in supporting use of clozapine [49,50] and psychosocial approaches for which ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

There are a few unmet needs in schizophrenia that can make a big difference in the prognosis and quality of life of patients. Treatment adherence is a big challenge for patients with schizophrenia ...

Non-adherence rates are incredibly high: about 75% of patients are thought to discontinue treatment. About a third of people with schizophrenia are resistant to conventional antipsychotic treatment.

Schizophrenia may be misdiagnosed as depression or bipolar disorder, which delays treatment and negatively impacts the prognosis, explained Megan Ehret, PharmD, MS, BCPP, of the University of ...

Lumateperone, an atypical antipsychotic, is currently approved under the brand name Caplyta for the treatment of schizophrenia in adults.

a second-generation antipsychotic often used for treatment-resistant schizophrenia, also ranked low (0.12). For reference, a significant or noticeable SMD result would be anything 0.5 or higher ...

serotonergic and adrenergic receptors – failed to improve the positive and negative schizophrenia symptom scale (PANSS) compared to conventional therapy in patients with treatment-resistant ...

While Cobenfy’s approval marks a significant step forward in schizophrenia treatment, questions remain about its long-term impact, particularly in addressing cognitive symptoms and its potential ...

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades. The drug, called Cobenfy and developed by US pharma giant ...

Preliminary results demonstrated a dose-dependent effect of ANAVEX ® 3-71 on two key EEG biomarkers in patients with schizophrenia. Treatment with ANAVEX ® 3-71 compared to placebo resulted in ...